Login to Your Account

CAT Gaining Cash Via High Court Decision; Abbott Can Seek Appeal

By Nuala Moran

Wednesday, February 2, 2005
LONDON - Cambridge Antibody Technology (CAT) Group plc received about £13.4 million (US$25 million) from Abbott Laboratories after the pharmaceutical company wasn't able to appeal a High Court judgment in CAT's favor and ordered to pay royalty arrears on sales of the blockbuster rheumatoid arthritis drug Humira. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription